SG Americas Securities’s Enzo Biochem, Inc. ENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-14,819
Closed -$51K 3304
2021
Q1
$51K Buy
14,819
+2,418
+19% +$7.52K ﹤0.01% 3158
2020
Q4
$31K Buy
+12,401
New +$27K ﹤0.01% 3181
2020
Q3
Sell
-24,087
Closed -$54K 3563
2020
Q2
$54K Buy
24,087
+7,606
+46% +$19.6K ﹤0.01% 3521
2020
Q1
$42K Buy
+16,481
New +$40.5K ﹤0.01% 3204
2019
Q3
Sell
-30,693
Closed -$103K 3256
2019
Q2
$103K Buy
30,693
+17,399
+131% +$61.3K ﹤0.01% 2802
2019
Q1
$36K Buy
+13,294
New +$43.5K ﹤0.01% 3236
2018
Q3
Sell
-11,692
Closed -$61K 3505
2018
Q2
$61K Sell
11,692
-3,519
-23% -$21.4K ﹤0.01% 3141
2018
Q1
$83K Sell
15,211
-7,006
-32% -$49.4K ﹤0.01% 3008
2017
Q4
$181K Buy
+22,217
New +$212K ﹤0.01% 2516
2016
Q4
Sell
-10,183
Closed -$52K 3523
2016
Q3
$52K Buy
+10,183
New +$60.8K ﹤0.01% 3178
2016
Q2
Sell
-22,700
Closed -$103K 3044
2016
Q1
$103K Buy
+22,700
New +$101K ﹤0.01% 2610
2014
Q3
Sell
-32,302
Closed -$170K 2879
2014
Q2
$170K Buy
+32,302
New +$140K ﹤0.01% 2119

Other funds holding ENZ

SG Americas Securities's ENZ Position: Q2 2021 in Review

SG Americas Securities sold out of Enzo Biochem, Inc. (ENZ) in Q2 2021, closing a stake of 14,819 shares — an estimated $51K sold.

SG Americas Securities first reported a position in ENZ in Q2 2014 and held it in 12 quarters. The position peaked at $181K in Q4 2017. 72 funds tracked by Wall St. Rank hold ENZ as of Q2 2021.

  • SG Americas Securities reported no remaining Enzo Biochem, Inc. position as of Q2 2021 after selling out during the quarter.
  • SG Americas Securities sold 14,819 Enzo Biochem, Inc. shares in Q2 2021, an estimated $51K.
  • SG Americas Securities first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 12 quarters.
  • SG Americas Securities's Enzo Biochem, Inc. position peaked at $181K in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2021.

Based on SG Americas Securities's 13F filing for Q2 2021, filed 12 Aug 2021.